$231 Million is the total value of Aisling Capital Management LP's 15 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 18.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $153,705,606 | -18.1% | 6,068,125 | 0.0% | 66.52% | +4.8% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $21,043,250 | -13.7% | 1,025,000 | 0.0% | 9.11% | +10.3% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $16,127,990 | -10.1% | 1,115,352 | 0.0% | 6.98% | +14.9% | |
| ELEV | Elevation Oncology Inc (ELEV) | $7,654,257 | -47.4% | 2,834,910 | 0.0% | 3.31% | -32.7% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $7,419,746 | -19.8% | 2,541,009 | 0.0% | 3.21% | +2.6% | |
| CMPS | Compass Pathways Plc (CMPS)sponsored ads | $5,825,580 | -27.4% | 964,500 | 0.0% | 2.52% | -7.2% | |
| GLUE | Monte Rosa Therapeutics Inc (GLUE) | $5,506,518 | -47.0% | 1,472,331 | 0.0% | 2.38% | -32.2% | |
| BMEA | Biomea Fusion Inc (BMEA) | $3,594,407 | -69.9% | 798,757 | 0.0% | 1.56% | -61.5% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $3,046,340 | -8.5% | 1,043,267 | 0.0% | 1.32% | +17.1% | |
| CalciMedica, Inc. (CALC) | $2,063,611 | -4.8% | 521,114 | 0.0% | 0.89% | +21.7% | ||
| Marker Therapeutics, Inc. (MRKR) | $1,706,571 | +26.3% | 314,286 | 0.0% | 0.74% | +61.7% | ||
| New | Tectonic Therapeutic Inc (TECX) | $1,385,918 | – | 84,148 | +100.0% | 0.60% | – | |
| RPHM | Reneo Pharmaceuticals Inc (RPHM) | $1,337,973 | -9.0% | 886,075 | 0.0% | 0.58% | +16.3% | |
| ACRS | Aclaris Therapeutics Inc (ACRS) | $477,901 | -11.3% | 434,455 | 0.0% | 0.21% | +13.7% | |
| VIRX | Viracta Therapeutics Inc (VIRX) | $156,896 | -46.7% | 288,571 | 0.0% | 0.07% | -32.0% | |
| SPRB | Exit | Spruce Biosciences, Inc. (SPRB) | $0 | – | -1,205,511 | -100.0% | -0.32% | – |
| AVRO | Exit | Avrobio, Inc. (AVRO) | $0 | – | -1,009,779 | -100.0% | -0.44% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 23 | Q2 2024 | 23.0% |
| Aclaris Theraputics Inc. (ACRS) | 23 | Q2 2024 | 6.6% |
| AVROBIO, Inc. (AVRO) | 22 | Q1 2024 | 13.6% |
| BridgeBio Pharma Inc. (BBIO) | 21 | Q2 2024 | 73.1% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| Atreca Inc. (BCEL) | 19 | Q4 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 18 | Q2 2024 | 17.2% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| POSEIDA THERAPEUTICS INC (PSTX) | 16 | Q2 2024 | 3.6% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-21 |
| 13F-HR | 2024-08-08 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.